How much does Zepbound cost?

As of August 2026, Zepbound self-pay costs $299 a month at the 2.5 mg starting dose, $399 at 5 mg, and $449 at every dose from 7.5 mg through 15 mg — but only if your prescription is written for the single-dose vial or the KwikPen². Lilly's published list price is $499 to $1,086.37 per 28-day fill¹. A commercially insured patient whose plan covers the drug can pay as little as $25 for up to a three-month prescription³. And since July 1, 2026, some Medicare Part D enrollees pay $50 a month⁵. Four very different numbers for the same molecule, and the thing that decides which one you get is mostly the device on the prescription.

The self-pay price is attached to a device, not just a dose

Zepbound ships in three presentations, and they do not share a price. The **single-dose vial** is labeled on LillyDirect as "Exclusively available through LillyDirect | Self-pay only" — you cannot get that price by walking into a drugstore, and insurance is not accepted against it². The **KwikPen** is marked "Select insurance accepted | Self-pay accepted," so it carries the self-pay price and can also run through a plan. The **single-dose Pen** is the insurance product: LillyDirect lists it only with the $25 savings-card price, and Lilly's savings page repeats on four separate panels that "The $299 per month is for the Zepbound KwikPen or vial, not Zepbound single-dose Pen"³. Vial and KwikPen self-pay pricing is identical, dose for dose: $299 at 2.5 mg, $399 at 5 mg, and $449 at 7.5, 10, 12.5, and 15 mg². Neither price includes what you inject with — the vial needs a needle and syringe purchased separately, and the KwikPen needs pen needles².

The $449 tier has a 45-day clock on it

The $449 figure at the four highest doses is not a standing price. It comes from the Zepbound Self Pay Journey Program, which since February 23, 2026 applies the offer automatically on a first purchase of 7.5 mg, 10 mg, 12.5 mg, or 15 mg⁴. Keeping it requires refilling within 45 days of the delivery date of your previous fill. Miss that window and the regular self-pay price applies: "$299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, $699 for 10 mg, $699 for 12.5 mg, and $699 for 15 mg"⁴. At 15 mg that is a $250 swing on a late refill, which makes the refill date a real cost variable rather than a scheduling detail. Lilly also notes that the discount may fail to apply at the register even when you qualify, in which case you pay the higher amount and file for post-transaction reimbursement afterward⁴. The self-pay card is open to anyone paying cash, including people who have insurance, on one condition: you agree not to seek reimbursement from any payer or apply the spending to a deductible⁴.

What commercial insurance changes

With commercial drug insurance that covers Zepbound, the savings card brings a single-dose Pen prescription to "as little as $25" for a one-, two-, or three-month fill³. Read the ceiling before you plan around that number. Card savings are capped at $100 per one-month prescription, $200 per two-month, and $300 per three-month, with a separate annual cap of $1,300 and a limit of 13 fills per calendar year³. If your plan leaves you owing $400 a month in coinsurance, the card takes $100 off it — you pay $300, not $25. The $25 headline describes patients whose plan cost-share was already low. Card terms as published expire December 31, 2026³.

If you have commercial insurance that does *not* cover Zepbound, there are two paths and they are priced differently. The single-dose Pen falls to "as low as $499" for a one-month fill, with savings computed as wholesale acquisition cost minus $499³. The KwikPen instead falls to the self-pay ladder — $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5 mg and above — capped at 11 fills a year rather than 13³. Same denial, same drug, $200 apart at the maintenance dose, decided by which device your prescriber wrote. Our insurance coverage guide walks through the prior authorization step that sits upstream of all of this.

The list price, and why it is rarely what you pay

Lilly publishes Zepbound's list price as "$499 - $1,086.37 per fill," defining a fill as 28 days and sourcing the figure to wholesale acquisition cost data accessed January 1, 2026¹. Wholesale acquisition cost is what Lilly charges wholesalers, not what a patient is billed, and Lilly says so directly on the same page¹. The company draws an explicit line between that number and its direct-to-patient price, which "is not the WAC, as the product is only available for purchase by cash paying patients"¹. Lilly does not publish which dose sits at the bottom of that range, and it does not publish a pharmacy counter cash price — retail cash prices are set by pharmacies, not by the manufacturer.

Medicare: the answer changed on July 1, 2026

Medicare Part D has long treated drugs used for weight loss as outside what it pays for, and the current arrangement is built around that rather than repealing it. Since July 1, 2026, CMS has run a short-term demonstration called the Medicare GLP-1 Bridge, which "will operate outside of the Medicare Part D benefit's coverage and payment flow" and runs through December 31, 2027⁶. Eligible enrollees pay a $50 copayment for a one-month supply⁵.

Two limits matter for anyone budgeting around it. First, the covered Zepbound presentation is the KwikPen and only the KwikPen — Medicare's own page states the program "doesn't cover single-dose Zepbound vials or pens," and CMS says the same in its plan guidance⁵⁷. Lilly's Medicare page repeats it: check that your prescription names the KwikPen before you take it to the pharmacy⁸. Second, the $50 does not behave like a normal copay. Because the drug is furnished outside Part D, the deductible does not apply, none of the $50 counts toward true out-of-pocket costs, and there is no low-income subsidy⁶. Eligibility starts at a BMI of 35, or 30 with a qualifying cardiac, blood pressure, or kidney condition, or 27 with prediabetes or a prior heart attack, stroke, or symptomatic peripheral artery disease⁵. A prior authorization is required, and once granted it holds through December 31, 2027 including dose increases⁵.

The exclusions cut the other way from what people expect. Type 2 diabetes, moderate-to-severe obstructive sleep apnea, and noncirrhotic MASH with significant fibrosis are all "eligible for Part D coverage," so beneficiaries with those diagnoses are *not* eligible for the Bridge and should go through their plan instead⁷. Zepbound carries a labeled use in moderate-to-severe obstructive sleep apnea in adults with obesity alongside its weight-management use, both under FDA application NDA 217806⁹. If OSA is your diagnosis, CMS names Zepbound explicitly as the example of a prescription that belongs in the Part D formulary exception process, not the Bridge⁷.

Before you fill, settle three things

Confirm the device, because it sets the price ceiling. Confirm the refill window if you are at 7.5 mg or above, because $449 and $699 are the same prescription filled on different dates. And confirm whether the price you were quoted is a self-pay price or a savings-card price, because the two have different rules about insurance, caps, and fill counts. For the same breakdown on the molecule rather than the brand, see how much tirzepatide costs; for how brand pricing compares with the compounded market, see compounded vs brand-name GLP-1. All figures here are Lilly's and Medicare's published prices as of August 2026 and change without notice; this is market context, not medical or financial advice.